ライフサイエンスコーパス: optimal dose

1 uptake of motexafin gadolinium (MGd) and its optimal dose.

2 he treatment of tuberculosis (TB), is not an optimal dose.

3 weeks, 175 mg/m(2) should be considered the optimal dose.

4 d as both the maximum-tolerated dose and the optimal dose.

5 ng dabigatran treatment and to determine the optimal dose.

6 , but there is no definitive evidence on the optimal dose.

7 teness of current designs for identifying an optimal dose.

8 oses in 10 steps starting at 1 : 1000 of the optimal dose.

9 on, but more research is needed to determine optimal doses.

10 itory than anti-CD154 mAb (100 microg/ml) at optimal doses.

11 ll fusion were enhanced, albeit at different optimal doses.

12 e in asthma, regimens of administration, and optimal doses.

13 aft models, ultimately curing 80% of mice at optimal doses.

14 eeded in this area to determine efficacy and optimal dosing.

15 luded in AREDS-type supplements, and at what optimal doses?

16 dose response mid-treatment and recommend an optimal dose adjustment.

17 expended to define chemopreventive activity, optimal dose, administration schedule, and toxicity for

18 Future RCTs should focus on identifying optimal dosing, administration timing, improving measure

19 To determine the optimal dose, adverse events (AEs), and efficacy of a pe

20 In addition to establishing optimal dose and administration of TAM, our study reveal

21 Determining optimal dose and delivery is essential to advance the fi

22 However, the optimal dose and duration are unknown.

23 (4) propose a study design to determine the optimal dose and duration of AAIT to achieve maximal eff

24 s who would benefit from prophylaxis and the optimal dose and duration of such prophylaxis should be

25 ng-bang control estimates the mathematically optimal dose and duration of the intervention for each m

26 y managed with corticosteroids; however, the optimal dose and duration remain to be determined.

27 confirm the effectiveness and determine the optimal dose and duration.

28 (700/1400 mg) were investigated to determine optimal dose and expand availability of treatment.

29 models of tuberculosis chemotherapy but its optimal dose and exposure in humans are unknown.

30 additional 10 infants receiving the defined optimal dose and for 3 infants receiving placebo.

31 dism require further studies to evaluate the optimal dose and frequency of administration to increase

32 growth dynamics and optimal control theory, optimal dose and frequency of medication customized for

33 ive pulmonary disease (COPD); however, their optimal dose and route of administration are uncertain.

34 in complex concentrates; ambiguity about the optimal dose and route of administration of vitamin K; a

35 However, the optimal dose and safe upper level of zinc have not been

36 The optimal dose and schedule and the appropriate patient po

37 The optimal dose and schedule for cladribine (2CdA) therapy

38 ecommended for routine clinical use, but the optimal dose and schedule for PBSC collection are still

39 resis beginning on day 5 was selected as the optimal dose and schedule for the mobilization of PBPCs.

40 We sought to define optimal dose and schedule of H56:IC31, an experimental T

41 ity associated with the current regimen, the optimal dose and schedule of paclitaxel in combination c

42 The safety and optimal dose and schedule of stem cell factor (SCF) admi

43 However, the optimal dose and the timeframe of administration of C3 a

44 s with acute myocardial infarction (MI), the optimal dose and the timing of its initiation have not b

45 e purpose of this study was to determine the optimal dose and timing of administration of sirolimus (

46 Further studies are needed to determine the optimal dose and timing of IVIG administration.

47 initiated a phase 1/2 study to determine the optimal dose and to assess its efficacy and safety in le

48 addresses key methodological issues, such as optimal dose and treatment duration, are needed.

49 (PK/PD) experiments, and hence the design of optimal doses and dose schedules for the treatment of tu

50 tic potential of these two drugs and predict optimal doses and dose scheduling, it is essential to un

51 studies and first clinical results to select optimal doses and regimens of everolimus to explore in f

52 rther studies will be required to define the optimal doses and schedules for epoetin alfa.

53 National guidelines for optimal doses and timing of vaccines after BMT are warra

54 tations may be useful to select patients for optimal doses and/or modalities of upfront AML therapy.

55 inflammatory diseases such as psoriasis, but optimal dosing and appropriate use of therapeutic drug m

56 colitis, controversies remain regarding the optimal dosing and delivery systems of the most fundamen

57 Once issues relating to optimal dosing and long-term effects of poloxamer 188 in

58 in-7 (IL-7) can boost CD4 T-cell counts, but optimal dosing and mechanisms of cellular increases need

59 elated laboratory and clinical efficacy, but optimal dosing and monitoring regimens for Africa remain

60 iogenic therapies and determination of their optimal dosing and scheduling.

61 Further studies are needed to determine optimal dosing and the relative ratio of DHA and EPA ome

62 rmine safety and efficacy and should explore optimal dosing and timing of methylxanthine administrati

63 Further efforts are needed to understand optimal dosing and treatment barriers to improve outcome

64 Elucidation of optimal dosing and treatment content is critical for hea

65 ers, genetic predisposition to atypical HUS, optimal dosing and withdrawal strategies for C5 inhibito

66 se-dependent manner, with 15 mg/kg being the optimal dose (and used in subsequent studies).

67 iological efficacy of exercise, identify the optimal "dose", and pinpoint mechanisms of action.

68 e similarly treated with 0.5 mg simvastatin (optimal dose) and daily intraperitoneal injections of CO

69 s are warranted to elucidate their efficacy, optimal dose, and long-term safety.

70 We examined specificity of FA, optimal doses, and therapeutic windows for neuroprotecti

71 s, and dosing algorithms, but clarity on the optimal dosing approach is lacking.Objectives: To charac

72 In sublingual immunotherapy, optimal doses are a key factor for therapeutic outcomes.

73 e safety and efficacy profiles or what their optimal doses are.

74 anations for why antibiotics differ in their optimal dosing are lacking, limiting our ability to pred

75 all-cause mortality and incident CVD with an optimal dose at 8,763 (aHR: 0.40; 95% CI: 0.38-0.43) and

76 In order to determine the optimal dose at which 4-MTBITC protects cell death, the

77 G(40kd) IFN alpha-2a dose appeared to be the optimal dose based on sustained virological response and

78 ther investigation is warranted to determine optimal dosing based on age and weight.

79 r optimizing antimicrobial use include using optimal dosing based on the manufacturer's instructions

80 effective oral medication to treat SCA, and optimal dosing benefits from pharmacokinetic (PK)-based

81 trations are well defined, identification of optimal dosing can be time consuming, and treatment is f

82 t that continued therapy with ruxolitinib at optimal doses contributes to the benefits seen, includin

83 The optimal doses (defined by individual study results) of t

84 tion, including the mechanism of action; the optimal dose; definitive indications; ultimate safety; a

85 In larger tumor, VMAT provided the optimal dose distribution and sparing to heart.

86 uantities of gp96 5-10 times larger than the optimal dose does not elicit tumor immunity.

87 ) mafosfamide was performed to determine the optimal dose, dose-limiting toxicities, and incidence an

88 ss, important questions remain regarding the optimal dose, duration, and mechanisms of action in the

89 ditional research is necessary to assess the optimal dose, duration, and probiotic strain or strains

90 philic leukemia (CEL), little is known about optimal dosing, duration of treatment, and the possibili

91 aximum signal-to-noise ratio (SNR), the mean optimal dose for a 60-min uptake period ranged from 366

92 vity profile which can be used to design the optimal dose for a patient.

93 reclinical and clinical data to identify the optimal dose for an antiangiogenesis agent, anti-EGFL7.

94 e-blind trial was conducted to determine the optimal dose for clinical efficacy of the SQ tree SLIT-t

95 reated with dopamine (5.0-7.0 microg/kg/min, optimal dose for contractile increase based on dose-resp

96 with atrial fibrillation, and to select the optimal dose for each individual.

97 The optimal dose for further development was 12 DU.

98 mab 20 mg/kg plus azacitidine represents the optimal dose for further studies.

99 arget interaction to support selection of an optimal dose for future efficacy testing.

100 rats spinalized as neonates, to identify the optimal dose for improved weight-supported stepping with

101 No epinephrine autoinjectors contain an optimal dose for infants weighing 10 kg or less.

102 The optimal dose for SIT was assessed using efficacy results

103 rvations, the 5 mg/kg dose was chosen as the optimal dose for subsequent behavioral studies.

104 The 400 U dose was recommended as the optimal dose for the phase III trial because of its good

105 erlotinib dose response study to define the optimal dose for the transplantation study.

106 d in tumor-xenografted mice to determine the optimal dose for therapy experiments.

107 Further studies are needed to define the optimal dose for use in combination with other antineopl

108 equently simulated, weight-banded once-daily optimal doses for children were lower than those current

109 Optimal dosing for bone health and, possibly, improved s

110 underlying pathomechanisms and identify the optimal dosing for the treatment of patients with this i

111 exposures and mortality in order to identify optimal dosing for tuberculous meningitis.

112 First, the optimal dose fractionation was 25-26 Gy in one fraction,

113 Optimal dosing frequency, corticosteroid-sparing effect

114 These include the optimal dose, frequency, and duration of methotrexate, a

115 linical use of CCP to treat IC patients, the optimal dose, frequency/schedule, and duration of CCP tr

116 treatment or undertreatment (relative to the optimal dose) further increased the mortality risk.

117 or use in combination regimens; however, the optimal dose has not been defined and final safety and e

118 ould be a flexible and inclusive option, yet optimal dosing has not been established across sex and g

119 randomized, controlled trial to evaluate the optimal dose, immunogenicity, safety and immune persiste

120 er than that provided by the therapeutically optimal dose in preclinical studies.

121 However, its optimal dosing in this subgroup has not been studied.

122 dies, using early MPEP treatment (15 min) at optimal doses, infarct volume was reduced by 44% at 72 h

123 Optimal dosing interval for maximal CRT reduction may be

124 The optimal dosing interval for zoledronic acid is uncertain

125 It is also observed that the averaged optimal dose is decreasing as a function of the initial

126 The optimal dose is found by titration and is not predicted

127 y in ST-elevation myocardial infarction, the optimal dose is unclear.

128 eatography (ERCP) in high-risk patients, the optimal dose is unknown, and pancreatitis incidence rema

129 However, the optimal dose is unknown.

130 ere is an appropriate patient population and optimal dose (LDL concentration) for the treatment of sy

131 Deutetrabenazine or placebo was titrated to optimal dose level over 8 weeks and maintained for 4 wee

132 down designs treated only 35% of patients at optimal dose levels versus 55% for Bayesian adaptive des

133 on of mouse or human RPGR-ORF15 vector at an optimal dose maintained the expression of RPGR-ORF15 thr

134 factor (VEGF).After the establishment of an optimal dose, minocycline treated HASMC were exposed to

135 to review practical guidelines in regard to optimal dosing, monitoring, managing common side effects

136 all trials that examined the association of optimal-dose mTORi with calcineurin inhibitor (CNI) have

137 all trials that examined the association of optimal-dose mTORi with Calcineurin Inhibitor (CNI) have

138 CY has a narrow therapeutic window, with an optimal dose not exceeding 200 mg/m(2).

139 An optimal dose of 10(7) tissue culture infectious dose 50

140 full length protein to the membrane with an optimal dose of 100 microM in CHO-K1 cells, while diC8 f

141 3.82 log10 colony-forming units (CFU)/mL, at optimal dose of 2 g once-daily.

142 The porcine kidney study identified an optimal dose of 80 mg (equivalent to 120 mg in human kid

143 ventilator-supported patients; however, the optimal dose of a bronchodilator from a MDI is unknown.

144 d that there might be sex differences in the optimal dose of ACE inhibitors or ARBs and beta blockers

145 ease risk through adiposity changes, but the optimal dose of activity is unknown.

146 SON (3.0 mL) compared with only 26% with the optimal dose of ALBUNEX (0.22 mL/kg) (p < 0.001).

147 The optimal dose of AMD3100 was found to be 5.0 mg/kg.

148 Combining an optimal dose of an NSAID with an appropriate dose of ace

149 The optimal dose of aspirin for most clinical situations is

150 mized, open-label clinical trial testing the optimal dose of aspirin for secondary prevention of athe

151 was well organized versus that formed by the optimal dose of BMP.

152 ofetil (MMF), it remains unclear what is the optimal dose of CsA beyond the first 6 to 12 months afte

153 t as effective in preventing bone loss as an optimal dose of estrogen.

154 The optimal dose of gB appeared to be between 5 and 30 micro

155 In this work, the optimal dose of glucose oxidase and xylanase were (30 an

156 The optimal dose of granulocyte colony-stimulating factor (G

157 sight into important questions regarding the optimal dose of inhaled nitric oxide, potential adverse

158 The optimal dose of interferon-alfa (IFN) for chronic myeloi

159 The optimal dose of isoniazid and its individual contributio

160 Define the optimal dose of isoniazid for patients with isoniazid-re

161 rsus MMR(+) normal tissues by predicting the optimal dose of IUdR and optimal timing for IR treatment

162 The optimal dose of IV plerixafor was determined to be 0.32

163 racterised the pharmacokinetics, safety, and optimal dose of linezolid in children treated for MDR-TB

164 The optimal dose of Mirococept in pig kidney was 80 mg.

165 -minute walk test distance from baseline, an optimal dose of neladenoson was not identified.

166 Group B received the optimal dose of O6-BG for 2, 4, 7, or 14 days after surg

167 Data to inform surgeons on the optimal dose of opioids to prescribe after common genera

168 ontrast occurred in 74% of patients with the optimal dose of OPTISON (3.0 mL) compared with only 26%

169 Protocol 9342 was initiated to determine the optimal dose of paclitaxel administered as a 3-hour infu

170 Our data suggest that the optimal dose of perflubron to achieve the lowest oxygena

171 a level identical to that obtained with the optimal dose of peripheral l-DOPA.

172 The optimal dose of plasmid vaccine encoding full-length Ag2

173 For the time-window study, the optimal dose of progesterone was given starting at 3, 6

174 gs across different regions and identify the optimal dose of programming to mitigate unhealthy zBMI g

175 The average optimal dose of risperidone in elderly dementia patients

176 The optimal dose of SS1scFvSA for pretargeting was 600 micro

177 The optimal dose of tacrolimus appears to be >1 mg but < or=

178 Determination of the optimal dose of TBI for allogeneic transplantation is co

179 s with solid tumors to define the safety and optimal dose of the combination regimen and to assess ph

180 We sought to determine the optimal dose of the selective endothelin A (ET(A)) recep

181 is required to ensure administration of the optimal dose of unfractionated heparin.

182 Exposure of the rabbit eye in vivo to an optimal dose of UVB produced an increase in the PGE2 lev

183 An optimal dose of WYE-132 achieved a substantial regressio

184 All animals receiving optimal doses of 2H7-Fc-C825 followed by (90)Y-DOTA were

185 evaluable population (n = 39) found that the optimal doses of aldesleukin to induce 10% and 20% incre

186 levels of proliferation upon stimulation by optimal doses of anti-CD3, suggesting the lack of a cost

187 Mice immunized with optimal doses of autologous tumor-derived gp96 resist a

188 sistant schizophrenia who were maintained on optimal doses of clozapine (400-1200 mg/day) were admini

189 Hsp90 release was stimulated with optimal doses of estradiol, IL-1, and TNF-alpha (10 ng/m

190 were obtained in cultures supplemented with optimal doses of FL + IL-7 + IL-3.

191 cts with grass allergen and challenging with optimal doses of grass, birch, recombinant house dust mi

192 Application of sub-optimal doses of morphine in electroacupuncture-treated

193 From these 30.7% of patients took optimal doses of non-selective B -blockers.

194 Although optimal doses of oral glucocorticoids for pulmonary sarc

195 Immunization with optimal doses of RSV F antigens in the presence of GLA-S

196 ors and indomethacin, and treatment with sub-optimal doses of signal transduction inhibitors, affect

197 Two optimal doses of SS (12.5 and 100 nM) and curcumin (2.5

198 n of Akt to approximately the same extent as optimal doses of wortmannin and LY294002, known inhibito

199 Our report warrants the need to establish optimal dosing of AL in adults and to alert clinicians a

200 Identifying optimal dosing of antibiotics has proven challenging-som

201 Optimal dosing of carboplatin in the high-dose setting w

202 Further studies are needed to determine optimal dosing of CNIs in the elderly.

203 Pharmacokinetic modeling suggested that optimal dosing of eptifibatide would be obtained with a

204 y used successfully to define the safety and optimal dosing of human spinal stem cells after grafting

205 ant information for future studies with more optimal dosing of LMW-DS for the prevention of IBMIR in

206 of SSRIs; there is a lack of data regarding optimal dosing of medications for children.

207 Optimal dosing of PRIT plus venetoclax cured 100% of mic

208 Optimal dosing of rabbit antithymocyte globulin (rATG) i

209 Whether patients receive optimal dosing of secondary prevention medications at th

210 ive efficacy in human cancer trials, but the optimal dosing of such agents must still be determined e

211 ditional studies are required to clarify the optimal dosing of tenapanor in patients with CKD-related

212 reduce the placebo response and examine the optimal dosing of TMS for adolescents with TRD.

213 pplied to observational studies to determine optimal dosing of vancomycin for methicillin-resistant S

214 We sought to identify the optimal dosing of VOR for effective serial reversal of H

215 e was only a slight (1 MBq/kg) dependence of optimal dose on patient weight but a larger dependence o

216 ever, these reports have not established the optimal dosing or ideal timing of the administration of

217 s, the change in statin prescribing rates at optimal dose over time was not significantly different f

218 ully ascertain the therapeutic potential and optimal dosing paradigm of a post-ischemic treatment wit

219 patient stratification and determination of optimal dosing paradigms while also facilitating the dis

220 owledge of old and new mechanisms of action, optimal doses, pharmacokinetic behavior and drug interac

221 ponsiveness of blood lymphocytes in vitro to optimal dose phytohemagglutinin (PHA) was reduced on day

222 More research on the optimal dose, preparation, and route of application inte

223 However, the optimal dosing protocol and target exposure in children

224 The optimal dosing protocol for rabbit anti-thymocyte globul

225 and warrant further studies to establish the optimal dosing regimen and efficacy.

226 he treatment of pediatric uveitis, including optimal dosing regimen and long-term efficacy.

227 ide mass of up to 50 ug was confirmed as the optimal dosing regimen for (68)Ga-satoreotide trizoxetan

228 ) effect and the tumor microenvironment, the optimal dosing regimen for carrier-mediated agents, and

229 However, the optimal dosing regimen in settings in which human immuno

230 properties of the drug and to rationalize an optimal dosing regimen in the clinic, a method is needed

231 ents with the higher dosage suggest that the optimal dosing regimen is <50 mg/h.

232 r define the efficacy, long-term safety, and optimal dosing regimen of rituximab in this setting.

233 The safety and optimal dosing regimen of the most effective topical ant

234 ill demand strong translational evidence, an optimal dosing regimen, and better tolerability.

235 Studies to investigate the optimal dosing regimen, duration of clinical benefit, an

236 c studies are therefore needed to define the optimal dosing regimen.

237 namic behavior of each class of drug so that optimal dosing regimens can be designed.

238 oing clinical trials will help determine the optimal dosing regimens for all of these agents, as well

239 steroids, in reducing risk of colectomy, (6) optimal dosing regimens for intravenous corticosteroids

240 We determined optimal dosing regimens for neutrophil depletion and eva

241 more specific recommendations can be made on optimal dosing regimens for reversal; maintenance; and p

242 tudied with regards to specific indications, optimal dosing regimens, or treatment efficacy.

243 ignificant increase in statin prescribing at optimal dose relative to control (adjusted difference in

244 n K antagonists (VKAs) such as warfarin, yet optimal dosing remains uncertain.

245 icacious, producing 80% and 100% survival at optimal doses, respectively.

246 to a therapeutic approach and help establish optimal dose-response curves for training.

247 Trials are needed to determine the optimal dose, route, and duration of octreotide treatmen

248 ials, evaluating the safety, reactogenicity, optimal doses, routes of administration, and schedules f

249 age 1.72 IU oxytocin every third day was the optimal dose schedule from stage 1 based on its Bayesian

250 The primary objective was to assess the optimal dose schedule of venetoclax with 5 + 2.

251 topotecan may necessitate a reevaluation of optimal dose schedule, with the possible incorporation o

252 challenges, however, remain to define their optimal dosing schedule and duration, sequencing, and in

253 ing and experimental approach to identify an optimal dosing schedule for osimertinib and dacomitinib

254 inical trials are warranted to determine the optimal dosing schedule of rituximab, the potential for

255 nce and the quantitative model can determine optimal dosing schedule to enhance the effectiveness of

256 uture studies are warranted to determine the optimal dosing schedule to improve therapeutic efficacy

257 intervals in ongoing trials to determine an optimal dosing schedule.

258 The optimal dose, schedule, and number of cycles of postremi

259 been made for radiotherapy but questions of optimal dose, schedule, timing and treatment volume rema

260 Further exploration of the optimal dose/schedule and correlation with biologic end

261 el of intracellular tuberculosis to identify optimal dose schedules and exposures of moxifloxacin and

262 cokinetic studies were encouraged to develop optimal dosing schedules based on therapeutic ranges.

263 However, optimal dosing schedules depend on the properties of met

264 During the last four decades, optimal dosing schedules have produced a therapeutic gai

265 population analysis methods, can facilitate optimal dose selection for children and pregnant women.

266 Its optimal dose still needs to be determined.

267 tics, including autoinduction, and determine optimal dosing strategies for short-course rifapentine-b

268 Optimal dosing strategies for SKPT recipients remain to

269 Optimal dosing strategies have not been established for

270 Although used for more than 20 years, optimal dosing strategies of most immunosuppressants hav

271 e still needed to answer questions regarding optimal dosing strategies.

272 g the outcome of chemotherapy and developing optimal dosing strategies.

273 The optimal dosing strategy and duration of MMF treatment ha

274 The optimal dosing strategy and feasibility for combination

275 Future research should assess the optimal dosing strategy for rifampicin, at doses higher

276 However, the optimal dosing strategy is unclear and conflicting evide

277 eroids may be of value; safety, efficacy and optimal dosing strategy need prospective appraisal in a

278 The optimal dosing strategy of low-molecular-weight heparins

279 eridol in schizophrenic patients requires an optimal dose that blocks the brain dopamine D2 receptors

280 tro/in vivo PK studies were conducted and an optimal dose that depletes NK cells and NK cell function

281 IT) topotecan was performed to determine the optimal dose, the dose-limiting toxic effects, and the i

282 most appropriate osmotherapeutic agent, the optimal dose, the safest and most effective mode of admi

283 The optimal dose, time to start, and duration of treatment f

284 Further work is needed to determine the optimal dose, timing and location for insemination.

285 urther studies are necessary to identify the optimal dose, timing, and route of administration of EGF

286 future studies with additional focus on the optimal dosing, timing, and interaction with concurrent

287 ped here allows one to directly estimate the optimal dose to inject for specific clinical scans and p

288 ng study identified 148 MBq (4.0 mCi) as the optimal dose to obtain diagnostic-quality PET/CT images.

289 e wild-type C57BL/6 animals to determine the optimal dose to test in SR-/- mice.

290 When used in optimal doses to treat patients with heart failure, reni

291 investigation might be aimed at elucidating optimal dosing to minimize adverse events without detrim

292 We determined the optimal dose-to-imaging interval and safety of FME using

293 tients who received 13 days of treatment, at optimal doses, using a biphasic model to describe first-

294 al overall survival rates for patients with "optimal" dose-volume histogram coverage versus "suboptim

295 day achieved a CFR > 90% in infants, but the optimal dose was 20 mg/kg/day in older children.

296 Baseline statin prescribing rates at the optimal dose were 40.3% in the control arm, 39.1% in the

297 Optimal doses were defined as the dose achieving greater

298 ld allow more patients to be treated at near-optimal doses while controlling for excessive toxicity.

299 f extending continuous-infusion O6-BG at the optimal dose with intracranially implanted carmustine wa

300 may be the most useful method in determining optimal dosing without the risk of disease exacerbation.